ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31

ALNYLAM PHARMACEUTICALS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026

$233.29+1.46 (+0.63%)

Close on Oct 19, 2026

Market cap: $32.26B
P/E (TTM): 43.4
Dividend yield: –

ALNYLAM PHARMACEUTICALS, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31
Revenue	3,714	2,248	1,828	1,037	844	493	220	75	90	47	–	–	–	–	–	100	101	96
Cost of Revenue	677	307	268	140	115	74	25	1.80	0	–	–	–	–	–	–	–	–	–
Gross Profit	3,037	1,942	1,560	897	729	419	195	73	90	–	–	–	–	–	–	–	–	–
Research & Development	1,320	1,126	1,004	883	792	655	655	505	391	382	276	190	113	87	99	106	109	97
Selling, General & Admin	1,211	976	796	771	621	588	479	382	199	89	–	–	–	–	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	199	89	61	45	27	45	38	38	40	27
Advertising Expenses	36	30	12	12	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Expenses	–	–	–	–	–	–	–	–	590	472	337	456	140	196	138	144	149	124
Total Costs & Expenses	3,212	2,425	2,110	1,822	1,553	1,321	1,159	890	590	472	–	–	–	–	–	–	–	–
Operating Income	502	-177	-282	-785	-709	-828	-939	-815	-500	-425	-296	-405	-93	-129	-55	-44	-48	-28
Interest Expense	253	142	121	156	143	84	0	0	–	–	–	–	–	–	–	–	–	0.87
Interest & Investment Income	111	122	96	25	1.58	12	33	29	–	–	–	–	–	0.98	1.21	2.31	5.39	14
Income from Equity Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	-4.52	-3.51	-7.64	-4.91	-9.29
Other Non-Operating Income	-178	-200	-151	-342	-143	-27	54	54	9.21	14	5.94	4.38	1.02	13	-2.83	1.07	1.10	2.31
Gain (Loss) on Investments	-2.31	-3.02	-17	-33	56	54	11	3.56	-1.89	6.98	–	–	–	–	–	–	0.51	–
Legal Settlements	–	–	–	–	–	–	0	21	0	–	–	–	–	–	–	–	–	–
Pretax Income	323	-377	-434	-1,127	-852	-856	-885	-761	-491	-410	-290	-401	-92	-117	-58	-43	-47	-26
Income Tax Expense	9.41	-99	6.73	4.16	0.68	2.68	0.86	0.82	0	0	0	-40	-2.70	-11	0	0.51	0.58	0.72
Net Income incl. Noncontrolling Interests	–	–	–	-1,131	-853	-858	-886	-761	-491	-410	–	–	–	–	–	–	–	–
Net Income	314	-278	-440	-1,131	-853	-858	-886	-761	-491	-410	-290	-360	-89	-106	-58	-44	-48	-26
EPS (Basic)(per share)	2.39	-2.18	-3.52	-9.30	-7.20	-7.46	-8.11	-7.57	-5.42	-4.79	-3.45	-4.85	-1.45	-2.11	-1.36	-1.04	-1.14	–
EPS (Diluted)(per share)	2.33	-2.18	-3.52	-9.30	-7.20	-7.46	-8.11	-7.57	-5.42	-4.79	-3.45	-4.85	-1.45	-2.11	-1.36	-1.04	-1.14	–
Shares Outstanding (Basic, Weighted)(shares)	131	128	125	122	118	115	109	101	91	86	84	74	62	50	42	42	–	–
Shares Outstanding (Diluted, Weighted)(shares)	135	128	125	122	118	115	109	101	91	86	84	74	62	50	42	42	–	–
EBITDA	557	-120	-228	-741	-661	-794	-922	-799	-488	-409	-277	-393	-83	-120	-50	-39	-42	-22

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 79.8%
Operating margin: 20.8%
Net margin: 15.3%
Return on equity, FY2025: 73.3%

Financial strength

Current ratio: 3.05
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 112.9%

Valuation

P/E ratio: 43.4
Price to sales: 6.71
Price to book: 23.82
Dividend yield: –